# Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

> **NCT06075927** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 29 (estimated)

## Conditions studied

- CMV Infection
- EBV Infection
- Stem Cell Transplant

## Interventions

- **BIOLOGICAL:** Virus specific T cells

## Key facts

- **NCT ID:** NCT06075927
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075927, "Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06075927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*